[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,607
  • Shares Outstanding, K 1,145
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,300 K
  • EBIT $ -31 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56

Options Overview Details

View History
  • Implied Volatility 206.26% (-61.26%)
  • Historical Volatility 140.86%
  • IV Percentile 19%
  • IV Rank 14.14%
  • IV High 306.98% on 07/07/26
  • IV Low 189.67% on 06/17/26
  • Expected Move (DTE 3) 0.85 (11.30%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 265
  • Open Int (30-Day) 200
  • Expected Range 6.67 to 8.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.51 +15.51%
on 08/14/26
12.49 -39.80%
on 07/20/26
-3.49 (-31.70%)
since 07/17/26
3-Month
3.15 +138.73%
on 05/21/26
29.32 -74.35%
on 05/28/26
+4.03 (+115.47%)
since 05/15/26
52-Week
3.02 +149.42%
on 05/12/26
49.60 -84.84%
on 09/25/25
-32.88 (-81.38%)
since 08/15/25

Most Recent Stories

More News
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform

AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism...

AKTX : 7.52 (-0.27%)
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload...

AKTX : 7.52 (-0.27%)
Akari Therapeutics Collaborates with Whitehawk Therapeutics to Expand ADC Payload Platform Potential

Akari Therapeutics (NASDAQ: AKTX) continues to execute on its strategy of advancing a differentiated payload platform designed for the next generation of antibody drug conjugates (ADCs). The

AKTX : 7.52 (-0.27%)
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform Watch the “What...

AKTX : 7.52 (-0.27%)
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing...

AKTX : 7.52 (-0.27%)
Akari Therapeutics (AKTX) Is Advancing the Next Generation of Antibody Drug Conjugates Through Novel Payload Innovation

Akari Therapeutics is advancing a novel antibody-drug conjugate (ADC) payload designed to overcome the limitations of existing cancer therapies, with its lead candidate AKTX-101 approaching c

AKTX : 7.52 (-0.27%)
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing...

AKTX : 7.52 (-0.27%)
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

TAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing...

AKTX : 7.52 (-0.27%)
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026

Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON,...

AKTX : 7.52 (-0.27%)
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers  Watch the “What This Means” video here TAMPA, Fla. and...

AKTX : 7.52 (-0.27%)

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

3rd Resistance Point 9.13
2nd Resistance Point 8.61
1st Resistance Point 8.07
Last Price 7.52
1st Support Level 7.01
2nd Support Level 6.49
3rd Support Level 5.95

See More

52-Week High 49.60
Fibonacci 61.8% 31.80
Fibonacci 50% 26.31
Fibonacci 38.2% 20.81
Last Price 7.52
52-Week Low 3.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.